The strong sales performance of Ryoncil, particularly the US$30.3 million in the March quarter and approaching $100 million in cumulative revenue, indicates successful market adoption of this first FDA-approved MSC therapy. This revenue strengthens Mesoblast's balance sheet and provides funding for label extensions and late-stage programs. The upcoming R&D Day may provide additional insights into the company's growth strategy and pipeline.
Price Chart
Executive Summary
Mesoblast Limited announced strong net sales of US$30.3 million for Ryoncil in the March quarter, with revenue approaching US$100 million since launch. This successful first-year performance strengthens the company's balance sheet and supports its pipeline development.
Key Facts
- Ryoncil net sales were US$30.3 million for the quarter ended March 31, 2026
- Revenue generated during the first year of Ryoncil launch approaches US$100 million
- Strong sales in February and March offset holiday seasonality in January
- Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)
Financial Impact
US$30.3 million in net sales for the quarter, with cumulative revenue approaching US$100 million since launch
Risk Factors
- The revenue figures are based on management's initial analysis and are subject to completion of financial closing procedures and audit
- Future performance may differ from current results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000041 |
| Exhibit: exhibit991ryoncilsalesup.htm | 0001345099-26-000041 |
| Document: 0001345099-26-000041-index-headers.html | 0001345099-26-000041 |
| Document: 0001345099-26-000041-index.html | 0001345099-26-000041 |
| Document: 0001345099-26-000041.txt | 0001345099-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $1.55 $1.55 | · 0.00% | ▼ −3.89% | $1.32 (−14.84%) |
Apr 30, 2026 25w ago | 6-K | $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.32 (−22.35%) |
Apr 16, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.32 (−17.50%) |
Apr 15, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers